Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jintrolong in SGA Children with Short Stature
NCT02375620Phase 2Active, not recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2015
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peg-somatropin in short stature (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: The change in height standard deviation scores (HT SDS) of the chronological age from baseline. Started Apr 2015; status: active, not recruiting.
02
Drugs
peg-somatropin
03
Conditions
short stature
Beyond the preview
Go deeper on NCT02375620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375620.